ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GLPG Galapagos NV

29.09
-0.36 (-1.22%)
04 May 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Galapagos NV NASDAQ:GLPG NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -0.36 -1.22% 29.09 28.70 54.54 29.435 28.80 29.10 125,690 05:00:04

Transparency notification received from The Capital Group

04/05/2021 9:01pm

GlobeNewswire Inc.


Galapagos NV (NASDAQ:GLPG)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Galapagos NV Charts.

Mechelen, Belgium; 4 May 2021; 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from The Capital Group Companies, Inc.

Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 30 April 2021 from The Capital Group Companies, Inc., who notified that it holds 4.65% of the current 65,511,581 outstanding Galapagos shares. The Capital Group Companies, Inc. thus crossed below the 5% threshold of Galapagos’ voting rights by disposing of voting securities on 29 April 2021. The full transparency notice is available on the Galapagos website.

About Capital GroupCapital Group controls Capital Bank & Trust Company and Capital Research & Management Company through its direct subsidiary Capital Group International, Inc. (“CGII”), controls four CGII investment management companies (Capital International, Inc.; Capital International Limited, Capital International Sàrl; and Capital International K.K.), which all together hold 3,049,333 of Galapagos’ voting rights, consisting of ordinary shares, which represents 4.65%.

About GalapagosGalapagos NV discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

ContactsInvestors:Elizabeth GoodwinVP Investor Relations+1 781 460 1784

Sofie Van GijselSenior Director Investor Relations+32 485 19 14 15ir@glpg.com

Media:Carmen VroonenGlobal Head Communications & Public Affairs+32 473 824 874

Kyra ObolenskySenior Director Corporate Communications+32 491 92 64 35communications@glpg.com

1  Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market

Attachment

  • Transparency notification received from The Capital Group

1 Year Galapagos NV Chart

1 Year Galapagos NV Chart

1 Month Galapagos NV Chart

1 Month Galapagos NV Chart

Your Recent History

Delayed Upgrade Clock